A recent fMRI study showed that dorsolateral prefrontal cortex (DLPFC) exerts an inhibitory control on pain pathways in humans. We investigated whether high-frequency rTMS over left DLPFC could ameliorate chronic migraine. Treatment consisted of 12 rTMS sessions, delivered in alternate days over left DLPFC. Sham rTMS was used as placebo. Eleven patients were randomly assigned to the rTMS (n=6) or to the placebo (n=5) treatment. Measures of attack frequency, headache index, number of abortive medications (outcome measures) were recorded in the month before, during and in the month after treatment. Subjects treated by rTMS showed a significant reduction of the outcome measures during and in the month after the treatment as compared to the month before treatment. No significant differences in the outcome measures were observed in the placebo group.
BRIGHINA F, PIAZZA A, VITELLO G, ALOISIO A, PALERMO A, DANIELE O, et al. (2004). rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. JOURNAL OF THE NEUROLOGICAL SCIENCES, 227, 67-71 [10.1016/j.jns.2004.08.008].
rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study
BRIGHINA, Filippo;VITELLO, Giorgia;DANIELE, Ornella;FIERRO, Brigida
2004-01-01
Abstract
A recent fMRI study showed that dorsolateral prefrontal cortex (DLPFC) exerts an inhibitory control on pain pathways in humans. We investigated whether high-frequency rTMS over left DLPFC could ameliorate chronic migraine. Treatment consisted of 12 rTMS sessions, delivered in alternate days over left DLPFC. Sham rTMS was used as placebo. Eleven patients were randomly assigned to the rTMS (n=6) or to the placebo (n=5) treatment. Measures of attack frequency, headache index, number of abortive medications (outcome measures) were recorded in the month before, during and in the month after treatment. Subjects treated by rTMS showed a significant reduction of the outcome measures during and in the month after the treatment as compared to the month before treatment. No significant differences in the outcome measures were observed in the placebo group.
| File | Dimensione | Formato | |
|---|---|---|---|
|
10447-14704.pdf
Solo gestori archvio
Dimensione
126.86 kB
Formato
Adobe PDF
|
126.86 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
